The US to Become Dominant THV Player, Forecasts GBI Research20 Jun 2013 • by Natalie Aster
The number of transcatheter aortic valve replacement (TAVR) procedures performed worldwide is projected to more than triple during the forecast period. The US is projected to surpass Germany to dominate the global transcatheter heart valve (THV) market in terms of procedure volumes. In the US, the approval of TAVR devices other than Edward's Sapien, the approval of second-generation prosthetics, and the expanded approval of TAVR for use in low-to-moderate-risk patients will also drive growth.
New product approvals in the US are expected to lead to a decline in prices. FDA approvals for Medtronic's CoreValve, Symetis' Acurate TA Valve, and Edwards' Sapien XT Valve are anticipated by 2014 and lower prices should sustain rapid TAVR adoption due to improved affordability.
Approval of TAVR in Japan will also provide a major boost to the Asia-Pacific region to gain significant share in terms of global procedure volumes. Japan is expected to approve Edwards' Sapien XT by late 2013, while Australia is expected to approve TAVR by 2017. This will provide a major boost in terms of the number of TAVR procedures performed, primarily due to the large elderly population in Japan. The Asia-Pacific region is expected to contribute significantly towards the number of TAVR procedures performed worldwide following approval in Japan and Australia, although the high cost could have a negative effect.
Mew report "Transcatheter Heart Valve Market Outlook, 2013 - Approval of Second Generation Prosthetics and Increasing Surgeons’ Confidence and Proficiency to Drive TAVR Procedure Volumes" by GBI Research examines the market, competitive landscape, and trends for the Transcatheter Heart Valves (THVs) market. The report provides comprehensive information on the key trends affecting these segments, and key analytical content related to market dynamics. The report also reviews the competitive landscape and provides a detailed analysis of the pipeline products for each segment, as well as details of important Mergers and Acquisitions (M&A) deals.
Transcatheter Heart Valve Market Outlook, 2013 - Approval of Second Generation Prosthetics and Increasing Surgeons’ Confidence and Proficiency to Drive TAVR Procedure Volumes
Published: June, 2013
Price: US$ 3,500.00
More information can be found in the report “Transcatheter Heart Valve Market Outlook, 2013 - Approval of Second Generation Prosthetics and Increasing Surgeons’ Confidence and Proficiency to Drive TAVR Procedure Volumes” by GBI Research.
To order the report or ask for sample pages contact email@example.com